BUTHIONINE SULFOXIMINE


Synonyms	Buthionine sulfoxamine Buthionine sulfoximine Butionine sulfoximine Dl-buthionine (s,r)-sulfoximine L-Buthionine(S,R)-Sulfoximine L-Buthionine-Sulfoximine NSC-381100
Status
Molecule Category	UNKNOWN
UNII	LW4108Q0BV


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WDFRNLYXRQXXFS-CVSPRKDYSA-N
Smiles	CCCC[S+](=N)([O-])CC[C@H](N)C(=O)O
InChI	InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7H,2-6,9H2,1H3,(H2-,10,11,12,13)/t7-,14?/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C8H18N2O3S
Molecular Weight	222.31
AlogP	0.64
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	7.0
Polar Surface Area	104.24
Molecular species	ZWITTERION
Aromatic Rings	0.0
Heavy Atoms	14.0

Assay Description	Organism	Bioactivity	Reference
Compound was tested for the inhibition of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 25.0 uM	Escherichia coli	9.7 %

Cross References

Resources	Reference
ChEMBL	CHEMBL1609891
FDA SRS	LW4108Q0BV
PubChem	21157

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).